BioRegenx, Inc.

BioRegenx, Inc.

生物技术研究

Chattanooga,TN 111 位关注者

BioRegenx is positioning itself as a forerunner in glycocalyx and microvascular regenerative health solutions.

关于我们

BioRegenx, Inc. is a holding company focused on regenerative health solutions and proactive healthcare that enables people to live better lives.?BioRegenx will capture market share by acquiring companies, products, and services on the leading edge of regenerative health and anti-aging.? BioRegenx leads the way in the science of the endothelial glycocalyx with patented imaging technology, the GlycoCheck? system and the patented formula, Endocalyx Pro, for regeneration of the glycocalyx and microvascular system. BioRegenx maintains exclusive rights to this comprehensive system and formula that has the backing of over 100 peer reviewed scientific studies. Combined with an effective direct-to-institution, direct-to-practitioner, consumer sales model, and other emerging sales models, BioRegenx is poised to capture a significant portion of the global health and wellness market with technology and exclusive patents. ? BioRegenx possesses vision, insight, and experience coupled with patented technology and products. These assets will allow BioRegenx to embrace the future of glycocalyx and microvascular health science and human well-being for a better present and future. The proven direct-to-practitioner and consumer model encourages participation in sales revenue and assures deep penetration into the health and wellness market. The current asset portfolio includes first-to-market, clinically relevant, patented technology for monitoring the glycocalyx and microvascular system and a proprietary, patented formula that improves and protects the endothelial glycocalyx. BioRegenx is positioning itself as a forerunner in the high-growth sector of glycocalyx and microvascular regenerative health solutions.

网站
https://bioregenx.com
所属行业
生物技术研究
规模
11-50 人
总部
Chattanooga,TN
类型
私人持股

地点

BioRegenx, Inc.员工

相似主页

融资

BioRegenx, Inc. 共 1 轮

上一轮

种子轮

US$183,000.00

Crunchbase 上查看更多信息